Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 2

Conditions

Melanoma 3Neoplasms 2Brain Neoplasms 2Thyroid Diseases 1Skin Neoplasms 1Ovarian Neoplasms 1Neuroma, Acoustic 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Adenolymphoma 1

Interventions

Temozolomide 94Radiotherapy 59Bevacizumab 59Radiosurgery 41Carboplatin 27Irinotecan 26Magnetic Resonance Spectroscopy 25Surgical Procedures, Operative 23Etoposide 22Carmustine 20Filgrastim 18Erlotinib Hydrochloride 17Cyclophosphamide 16Cisplatin 16Vincristine 15Lomustine 15Lapatinib 15Sorafenib 13Radiation 13Trastuzumab 12Nivolumab 12Imatinib Mesylate 12Thalidomide 11Surveys and Questionnaires 11Granulocyte Colony-Stimulating Factor 11Radiotherapy, Intensity-Modulated 10Aminolevulinic Acid 10temsirolimus 9Topotecan 9Thiotepa 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Brain Neoplasms × Fluorescein × Clear all
NCT04597801 2022-11-10

INVIVO

Technical University of Munich

Phase 2 Completed
210 enrolled
CNS

Brain Neoplasms

NCT02389530 2018-08-03

Use of Fluorescein Dye for the Removal of Brain Tumors

University of Pittsburgh

Completed
91 enrolled
CNS

Brain Neoplasms, Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡